Fenretinide

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer	2025/04/10	NCT06922539	Phase 1	Not yet recruiting	SciTech Development, Inc.
Study to Examine the Effects of Oral Fenretinide	2024/07/30	NCT06528457	Phase 2	Active, not recruiting	Island Pharmaceuticals
A Study to Evaluate the Safety of Fenretinide in Healthy Volunteers	2023/12/26	NCT06181760	Phase 1	Completed	Island Pharmaceuticals
Study of LAU-7b for the Treatment of COVID-19 Disease in Adults	2020/06/04	NCT04417257	Phase 2	Completed	Laurent Pharmaceuticals Inc.
Phase 1 Trial of ST-001 NanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma	2020/01/21	NCT04234048	Phase 1	Recruiting	SciTech Development, Inc.
Study of LAU-7b in the Treatment of Cystic Fibrosis in Adults	2017/08/29	NCT03265288	Phase 2	Completed	Laurent Pharmaceuticals Inc.
Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas	2015/07/13	NCT02495415	Phase 2	UNKNOWN	CerRx, Inc.
Safety Study of Fenretinide in Adult Patients With Cystic Fibrosis	2014/05/20	NCT02141958	Phase 1	Completed	Elias Matouk
Expanded Access Study of Fenretinide Lym-X-Sorb Plus Ketoconazole in Neuroblastoma	2014/03/03	NCT02075177	N/A	NO_LONGER_AVAILABLE	South Plains Oncology Consortium
Phase I Trial of IV Fenretinide (4-HPR) Plus IV Safingol for Patients With Relapsed Malignancies	2012/03/13	NCT01553071	Phase 1	Terminated	South Plains Oncology Consortium

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Related News

Island Pharmaceuticals Raises $6.22 Million to Advance Dengue Fever Treatment and Antiviral Pipeline

2 days ago

Island Pharmaceuticals raised $2.72 million through the exercise of listed options and secured an additional $3.5 million placement to support clinical development activities.

Island Pharmaceuticals Completes Patient Dosing in Phase 2b PROTECT Trial for Dengue Fever Treatment

5 months ago

Island Pharmaceuticals has successfully completed dosing of ten subjects in the Phase 2b treatment arm of the PROTECT trial, evaluating ISLA-101 for dengue fever treatment.

Island Pharmaceuticals Completes Phase 2b Dosing for ISLA-101 Dengue Fever Treatment

5 months ago

Island Pharmaceuticals has completed subject dosing for the phase 2b therapeutic arm of its PROTECT clinical trial, testing ISLA-101 as a treatment for dengue fever in 10 subjects.

Dengue Fever Clinical Trial Landscape Shows Active Global Research Efforts

6 months ago

A global review of dengue fever clinical trials reveals ongoing research across multiple regions and countries, with a focus on G7 and E7 nations.

SciTech Development Appoints John Chapman to Strategic Advisory Board

7 months ago

SciTech Development has appointed John Chapman, formerly of KPMG, to its Strategic Advisory Board as Senior Financial Advisor.

AI-Powered Research

Premium Access

Overview

Background

Indication

Associated Conditions